Cadrenal officer Pham proposes 40,000-share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cadrenal Therapeutics, Inc. (CVKD) officer Quang X. Pham reported a proposed sale of 40,000 common shares, with an aggregate market value of $148,400 and an approximate sale date of June 15, 2026. The notice names Merrill Lynch as broker and lists September 23, 2025, as the adoption date for a Rule 10b5-1 plan. It also reports prior sales between May 11 and June 12, 2026.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When was the Rule 10b5-1 plan for Quang X. Pham's proposed CVKD sale adopted?
AI-generated analysis. How Rhea-AI works. Not financial advice.